Twist Bioscience (NASDAQ: TWST) Drops on Wider EPS Loss Despite Revenue Beat

Twist Bioscience (NASDAQ: TWST) tumbled 6.97% to $56.19 after Q2 earnings revealed a widening loss per share despite beating revenue expectations. The synthetic biology platform company's struggle to convert AI-driven demand into profitability has renewed investor concerns about the company's path to sustainable earnings, despite revenue growth of 16.9% year-over-year.

Q2 2026 At a Glance

• Revenue beat analyst expectations with 16.9% year-over-year growth
• Operating loss widened as operating margin deteriorated to negative 31.7%
• Net loss margin of 19.6%, reflecting heavy operating expenditures outpacing gross profit expansion
• Gross margin of 51.6%, showing underlying product economics remain healthy but insufficient to cover operating costs

What Drove the Results

Twist's Q2 revenue beat reflects genuine demand tailwinds—AI model training and development requires synthetic DNA and molecular design capabilities that Twist provides. However, the company's ability to monetize this demand has been hampered by aggressive R&D spending and operating cost inflation. The negative 31.7% operating margin indicates the company is investing heavily in scaling infrastructure, customer acquisition, and platform development, betting that revenue growth will eventually lap these investments.

The widening EPS loss, despite revenue growth, suggests scale economics are not yet materializing. Gross margin of 51.6% is healthy and stable, but operating expenses are consuming more than 150% of gross profit—an unsustainable dynamic. Management's confidence in AI demand is evident in the growth rate, but the company must demonstrate a path to operating leverage or risk further shareholder dilution through equity financing.

Investor Takeaway

Twist Bioscience is caught between opportunity and profitability: AI demand is real and accelerating, yet the company's burn rate is rising faster than revenue. The stock is speculative, appropriate only for investors with high risk tolerance and conviction that the company will achieve operating leverage within 12–18 months. A repeat quarter of widening losses could trigger another sharp repricing lower.